株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品受託製造の世界市場

Pharmaceutical Contract Manufacturing

発行 Global Industry Analysts, Inc. 商品コード 236772
出版日 ページ情報 英文 347 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
医薬品受託製造の世界市場 Pharmaceutical Contract Manufacturing
出版日: 2017年01月01日 ページ情報: 英文 347 Pages
概要

当レポートでは、世界の医薬品受託製造市場について調査し、市場の概要と見通し、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 医薬品受託製造:概要
    • 現在および将来分析
    • 市場規模
    • 医薬品受託製造サービスは欧米がリード
    • 固定用量がCMO内で今なお人気
    • 注射型製剤がPCM市場の成長を牽引
    • PMC市場の機会
    • 市場促進因子
    • 明るい将来を実現するためには大きな変革が必要
  • 市場動向と促進因子
  • 競合環境
  • サービス概要
    • イントロダクション
    • 注射型薬剤
    • 固定用量製剤
    • 液状製剤
    • 医薬品受託製造の増加
    • 投資リスク
    • 品質保証リスク
    • 薬剤開発リスク
    • 買収リスク
    • クライアント依存リスク
  • 近年の業界活動
  • 主要参入企業
    • Aenova Group
    • Ajinomoto Althea, Inc.
    • Albany Molecular Research Inc.
    • Alcami Corporation
    • Baxter International, Inc.
    • Boehringer Ingelheim GmbH
    • Catalent Pharma Solutions, Inc.
    • Cobra Biologics Holding AB
    • CordenPharma International
    • Dishman Group
    • DPx Holdings B.V.
    • Fareva Group
    • Famar Health Care Services
    • Hospira, Inc.
    • Jubilant Life Sciences Limited
    • Kemwell Biopharma Pvt. Ltd.
    • Lonza Group Ltd.
    • LTS Lohmann Therapie-Systeme AG
    • NextPharma Technologies Holding Ltd.
    • ニプロファーマ株式会社
    • Recipharm AB
  • 世界市場見通し

第3章 市場

  • 米国
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-1535

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 112 companies including many key and niche players such as -

Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research Inc.
Alcami Corporation
Baxter International, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Pharmaceutical Contract Manufacturing - A Prelude
  • Current & Future Market Outlook
  • Sizing the Market
  • West Leads in PCM Services
  • Solid Dosage Remains Popular Among CMOs
  • Injectable-Dose Formulations to Spearhead Growth of the PCM Market
  • Opportunities Rife for PCM Growth
  • Key Market Drivers
  • Major Changes Imperative to Capitalize on Brighter Future Prospects

2. MARKET TRENDS & DRIVERS

  • Changing Face of the CMO Industry
  • Relevance of CMOs Increases in the Modern Pharma Industry
  • Patent Expiries Augur Good Tidings for the PCM Market
  • PCMs Gear Up to Tap Booming Biologics Market
  • Biotechnology Start-Ups Spur Demand for Contract Manufacturing
  • Service Differentiation - The Key to Future Success in Solid Dosage Formulations Manufacturing
  • Strong Growth in Injectables Market to Resonate in Contract Manufacturing
  • Developed Markets Dominate Sterile Injectables Contract Manufacturing Market
  • PCM Market for Vaccines Yet to Take Off
  • PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring
  • Smaller Production Batches are Here to Stay; Compel Facility Efficiency Improvements
  • Upstream Movement Becomes a Compulsion for Many
  • Need to Focus on Better Customer Services Emerges
  • Rising Drug Complexity Presses for Specialized Expertise
  • Adoption of Cutting-Edge Technologies to Radicalize PCM Environment
  • RABS technology
  • Quality by Design
  • Track & Trace Techniques
  • Disposable Processing Techniques
  • Upstream & Downstream Processes
  • Process Analytical Technology
  • Near Infrared Spectroscopy
  • Perfusion Technology Takes Center-stage as Quality and Cost Concerns Rise
  • Downstream Processes Get a Lift as CMOs Seek Ways to Improve Capacity
  • Biopharma Contract Manufacturing Surges Ahead
  • Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production
  • Contract Manufacturing of ADCs Continues to Rise
  • Competition to Surge in Biological Contract Manufacturing Market
  • CMOs Gear Up for Capacity Expansions to Address Growing Demand from Biopharma
  • Ballooning Global Population Offers Increased Growth Opportunities
    • Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)
  • Aging Population Boosts Opportunities for PCM
    • Table 2: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
    • Table 3: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)
    • Table 4: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
  • Increasing Healthcare Expenditure to Spur Demand for Contract Manufacturing of Generics
    • Table 5: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart)
    • Table 6: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart)
  • Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers
    • Table 7: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart)
  • Insourcing of Manufacturing Operations - An Emerging Threat to PCM
  • Vendor Switching- A Growing Concern for PCMs
  • New Challenges Threaten Prospects for CMOs
  • New Distribution Regulations Incites Changes in Operations

3. COMPETITIVE LANDSCAPE

  • PCM - A Highly Fragmented Industry Undergoing Consolidation
    • Table 8: Leading Players in the Global Finished Dose Pharmaceutical Contract Manufacturing Market (2015): Percentage Breakdown of Revenues for Aenova, Baxter, Catalent, Famar, Fareva, LTS Lohmann, Nipro, Patheon/DPx, Pfizer/Hospira, Vetter and Others (includes corresponding Graph/Chart)
    • Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart)
  • PCMs Battle Fierce Competition and Commoditization
  • Consolidation Wave Hits the Market
  • Select Key CMO Mergers and Acquisitions: 2014-2016
  • Changing Focus on M&A Activity
  • Investments Rise as CMOs Respond to Changing Market Needs
  • Capacity Expansions Become Popular Options for Building Integrated Service Offerings
  • Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings
  • Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs

4. SERVICE OVERVIEW

  • Introduction
  • Injectables (Injections, Vials, and IV solutions)
  • Solid Dosage Forms (SDFs) (Tablets and Capsules)
  • Liquid Dosage Forms (LDFs) (Syrups and Suspensions)
  • An Insight into the Rise of Pharmaceutical Contract Manufacturing
  • Investment Risks in Pharmaceutical Contract Manufacturing
  • Quality Assurance Risk
  • Drug Development Risk
  • Acquisition Risk
  • Client Dependency Risk

5. RECENT INDUSTRY ACTIVITY

  • KDPharma to Merge with Marine Ingredients
  • Suanfarma Acquires Stake in Idifarma
  • Recipharm Inks Long-Term Commercial Manufacturing Contract with Tillots
  • Propanc Inks Contract Manufacturing Deal with AmatsiQBiologicals
  • BioTechnique Commences Vaccine Manufacturing under Partnership with NPO
  • Piramal Pharma Solutions Acquires Ash Stevens
  • Saneca Sells Registration Dossiers for 20 Products to Xantis, Retains Manufacturing Rights
  • Evonik Takes Over Transferra
  • Famar to Acquire Roche's Leganes Site
  • Mylan Acquires Part Business of Renaissance
  • Averica and Dalton Pharma Ink Preferred Provider Agreement
  • AGC Asahi Glass Takes Over Biomeva
  • BioDuro and Formex Merge
  • Frontida Acquires Sun Pharma's US Manufacturing Facilities
  • Recipharm Inks Agreement to Take Over CDMO from Kemwell
  • Generic Specialties Takes Over Axcellerate Pharma
  • Pfizer Establishes Pfizer CentreOne Specialty CMO
  • Caisson Biotech Inks Manufacturing Agreement with CordenPharma
  • Brammer and Florida Biologix Merge
  • AAIPharma and Cambridge Major Laboratories Merge to form Alcami
  • Recipharm to Acquire Mitim
  • TxCell Signs CMO Deal with MaSTherCell
  • Boehringer Ingelheim to Commence First Biopharma CMO Pilot Project in China
  • Enteris Commences Contract Manufacturing Service at its Facility
  • Capsugel Takes Over Powdersize and Xcelience
  • Synerlab Acquires Alcala Farma
  • Recipharm Inks Deal to Take Over Majority Stake in Nitin Lifesciences
  • Pfizer Acquires Hospira
  • Avista Pharma Takes Over Scynexis CMO and Animal Health Businesses
  • Lonza and Nikon Team Up for New Contract Manufacturing Facility
  • Piramal Acquires Coldstream
  • SK Capital Takes Over Halo Pharmaceutical
  • FUJIFILM Acquires Kalon Biotherapeutics
  • Bayer Selects Cardinal Health as Contract Manufacturer for Xofigo(r)
  • Recipharm Takes Over Manufacturing Facility and Contracts from Flamel
  • Baring to Acquire Bushu Pharmaceuticals
  • Recipharm Takes Over Lusomedicameta
  • Strides Arcolab and Shasun to Merge
  • Kinex Pharmaceuticals Acquires QuaDPharma
  • Patheon Acquires Gallus BioPharmaceuticals
  • Packaging Coordinators Takes Over Penn Pharma
  • Sun Pharmaceutical Takes Over Pharmalucence
  • AMRI Acquires Oso Biopharmaceuticals Manufacturing
  • Carlyle Group Takes Over Sunsho Pharmaceutical
  • AMRI Acquires Cedarburg
  • Par Pharmaceutical to Take Over JHP
  • JLL Partners and Royal DSM Merger Businesses to form DPx
  • Meiji Holdings Buys Medreich Lifecare Limited
  • Emilia Group Takes Over Pharma Pac LLC
  • Emergent BioSolutions Takes Over Cangene Corporation

6. FOCUS ON SELECT PLAYERS

  • Aenova Group (Germany)
  • Ajinomoto Althea, Inc. (US)
  • Albany Molecular Research Inc. (US)
  • Alcami Corporation (US)
  • Baxter International, Inc. (US)
  • Boehringer Ingelheim GmbH (Germany)
  • Catalent Pharma Solutions, Inc. (US)
  • Cobra Biologics Holding AB (Sweden)
  • CordenPharma International (Germany)
  • Dishman Group (India)
  • DPx Holdings B.V. (US)
  • Fareva Group (Luxembourg)
  • Famar Health Care Services (Greece)
  • Hospira, Inc. (US)
  • Jubilant Life Sciences Limited (India)
  • Kemwell Biopharma Pvt. Ltd. (India)
  • Lonza Group Ltd. (Switzerland)
  • LTS Lohmann Therapie-Systeme AG (Germany)
  • NextPharma Technologies Holding Ltd. (UK)
  • Nipro Pharma Corporation (Japan)
  • Recipharm AB (Sweden)
  • Vetter Pharma International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE

    • Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 12: World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 15: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 21: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US PCM Market Overview
    • Domestic Contract Manufacturing Market Sees New Vigor
    • Competitive Landscape
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 24: The US 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 27: Canadian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Nipro Pharma Corporation - A Key Japanese Player
  • B. Market Analytics
    • Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 30: Japanese 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Market Overview
    • Injectables Segment Offers Promising Potential
    • Mammalian Cell Technology Dominates PCM Market
    • Competitive Scenario
    • Overview of Select Markets
      • Germany
      • Russia
  • B. Market Analytics
    • Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 33: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain and Rest of European Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
    • Table 34: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 36: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 37: French Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: French Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 39: French 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 40: German Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: German Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 42: German 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 43: Italian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 44: Italian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 45: Italian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
    • Key Player
  • B. Market Analytics
    • Table 46: UK Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 47: UK Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 48: UK 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 49: Spanish Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: Spanish Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 51: Spanish 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 52: Rest of European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 53: Rest of European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 54: Rest of European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Favorable Government Policies Transform China and India into PCM Hubs
    • Competitive Scenario
    • Overview of Select Key Markets
      • India
      • India - A Stronghold for Pharmaceutical Contract Manufacturing
      • Market Sees Transitory Turbulence
      • Indian PCMs Battle Soaring Costs
      • Outlook Remains Promising
      • China
      • China Presents Enormous Opportunities for Contract Manufacturing
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 55: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 56: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 57: Asia-Pacific 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 58: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 59: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 60: Rest of World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top